Table 4.
Regular and nonregular NSAID use and risk of glioma and glioblastoma by length of follow-up, NIH-AARP, 1996–2006
| ≤ 5.2 y |
>5.2 y |
|||
|---|---|---|---|---|
| Case (n) | HRa (95% CI) | Case (n) | HRa (95% CI) | |
| Glioma | ||||
| Aspirinb | ||||
| No use | 40 | 1.00 (Ref) | 35 | 1.00 (Ref) |
| Nonregular | 68 | 1.18 (0.80–1.75) | 67 | 1.25 (0.83–1.89) |
| Regular | 64 | 1.02 (0.68–1.54) | 63 | 1.34 (0.88–2.05) |
| Nonaspirin NSAIDsc | ||||
| No use | 79 | 1.00 (Ref) | 70 | 1.00 (Ref) |
| Nonregular | 68 | 0.99 (0.71–1.37) | 73 | 1.12 (0.80–1.56) |
| Regular | 24 | 0.89 (0.55–1.39) | 23 | 0.92 (0.57–1.48) |
| Glioblastoma | ||||
| Aspirinb | ||||
| No use | 31 | 1.00 (Ref) | 25 | 1.00 (Ref) |
| Nonregular | 51 | 1.15 (0.73–1.80) | 57 | 1.48 (0.92–2.37) |
| Regular | 47 | 0.95 (0.60–1.53) | 49 | 1.45 (0.89–2.38) |
| Nonaspirin NSAIDsc | ||||
| No use | 61 | 1.00 (Ref) | 57 | 1.00 (Ref) |
| Nonregular | 50 | 0.95 (0.65–1.38) | 59 | 1.09 (0.76–1.58) |
| Regular | 18 | 0.86 (0.51–1.45) | 16 | 0.78 (0.44–1.36) |
a
Adjusting for race, sex, and history of heart disease using age as time metric.
b
Four glioblastoma cases were missing for aspirin.
c
Three glioblastoma cases and 1 glioma case were missing for nonaspirin NSAIDs.